{
    "clinical_study": {
        "@rank": "90618", 
        "arm_group": {
            "arm_group_label": "Vismodegib", 
            "arm_group_type": "Experimental", 
            "description": "Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to evaluate an investigational drug (Vismodegib) for\n      Pontine Glioma that is growing or has come back (reoccurred). This study will look at the\n      tumors response to the study drug, Vismodegib, and will also look at the safety and\n      tolerability of Vismodegib.\n\n      Vismodegib has been tested in multiple adult clinical trials and one pediatric trial.\n      Laboratory testing in pontine gliomas suggests that this drug may be effective in treating\n      this disease."
        }, 
        "brief_title": "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma", 
        "completion_date": {
            "#text": "April 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Pontine Glioma", 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Pontine Glioma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have radiographically proven diffuse intrinsic pontine glioma and\n             confirmation of residual disease after initial therapy or at the time of\n             recurrence/progression as confirmed by MRI of the brain\n\n          -  Subjects must be age \u22653 years and \u2264 18 years\n\n          -  Diffuse intrinsic pontine glioma with measurable disease after receiving radiotherapy\n             either concurrent with or followed by \u2264 2 prior courses of chemotherapy\n\n          -  Measurable disease as defined by:\n\n        Measurable tumor >10mm by MRI\n\n          -  Karnofsky performance status (PS) 60-100% (for patients > 16 years of age) OR Lansky\n             PS 60-100% (for patients \u2264 16 years of age)\n\n          -  Body surface area > 0.67 m2 and \u2264 2.21 m2\n\n          -  Life expectancy of at least 2 months\n\n          -  A negative urine pregnancy test is required for female participants of child bearing\n             potential (\u226513 years of age or after onset of menses)\n\n          -  Acceptable liver function as defined by:\n\n               1. Bilirubin \u2264 1.5 times upper limit of normal\n\n               2. AST (SGOT), ALT (SGPT) and Alkaline phosphatase \u2264 2.5 times upper limit of\n                  normal\n\n          -  Creatinine clearance or radioisotope GFR \u2265 70 mL/min OR serum creatinine based on age\n             as follows:\n\n               -  0.8 mg/dL (for patients \u2264 5 years of age)\n\n               -  1.0 mg/dL (for patients 6 to 10 years of age)\n\n               -  1.2 mg/dL (for patients 11 to 15 years of age)\n\n               -  1.5 mg/dL (for patients > 15 years of age)\n\n          -  Acceptable hematologic status as defined by:\n\n               1. Granulocyte \u2265 1500 cells/mm3\n\n               2. Platelet count \u2265 100,000 (plt/mm3)\n\n               3. Serum albumin \u2265 2.5 g/dL\n\n          -  Urinalysis:\n\n             a. No clinically significant abnormalities\n\n          -  Acceptable coagulation status as defined by:\n\n               1. PT/INR less than 1.5\n\n               2. PTT within normal limits\n\n          -  Subjects must be able to swallow and retain oral medication\n\n          -  Female post-pubertal study subjects need to agree to use one of the more effective\n             birth control methods during treatment and for 7 (seven) months after treatment is\n             stopped. These methods include total abstinence (no sex), oral contraceptives (\"the\n             pill\"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or\n             medroxyprogesterone acetate injections (Depo-provera shots).\n\n          -  Male post-pubertal study subjects need to agree to use condoms with spermicide, even\n             after a vasectomy, during sexual intercourse with female partners while being treated\n             with Erivedge capsule and for 2 months after the last dose to avoid exposing an\n             embryo or fetus to Vismodegib.\n\n          -  Voluntarily signed and dated a written IRB-approved informed consent by parent or\n             legal guardian of subject\n\n        Exclusion Criteria:\n\n          -  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery,\n             immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in\n             the protocol. Patients must have discontinued the above cancer therapies for\n             generally about 3 weeks (8 weeks for radiotherapy) prior to the first dose of study\n             medication, as well as recovered from toxicity (to \u2264 than grade 2 except for\n             alopecia) induced by previous treatments.\n\n          -  Currently receiving another investigational medicinal product.\n\n          -  Uncontrolled concurrent illness including, but not limited to:\n\n               1. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic\n                  therapy\n\n               2. Diarrhea of any cause \u2265 CTCAE grade 2\n\n               3. Psychiatric illness/social situations that would compromise patient safety or\n                  limit compliance with study requirements including maintenance of a\n                  compliance/pill diary\n\n               4. Any kind of malabsorption syndrome significantly affecting gastrointestinal\n                  function\n\n          -  Pregnant or nursing female patients. NOTE: If a female patient becomes pregnant or\n             suspects that she is pregnant while participating in this study, she should stop\n             taking study drug and immediately inform her treating physician immediately.\n\n          -  Prior therapy with a Hedgehog inhibitor\n\n          -  Unwillingness or inability to comply with procedures required in this protocol\n\n          -  Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other\n             conditions) that could compromise protocol objectives in the opinion of the\n             investigator and/or the sponsor.\n\n          -  History of Congestive Heart Failure (CHF) or ventricular arrhythmia requiring\n             medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774253", 
            "org_study_id": "NMTRCPG007"
        }, 
        "intervention": {
            "arm_group_label": "Vismodegib", 
            "intervention_name": "Vismodegib", 
            "intervention_type": "Drug", 
            "other_name": "Erivedge"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "DIPG", 
        "lastchanged_date": "February 5, 2014", 
        "link": {
            "description": "Neuroblastoma and Medulloblastoma Translational Research Consortium", 
            "url": "http://nmtrc.squarespace.com/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "schimienti@phoenixchildrens.com", 
                    "last_name": "Sam Chimienti", 
                    "phone": "602-546-0188"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Phoenix Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Amy Rosenfeld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shannon.mackeigan@helendevoschildrens.org", 
                    "last_name": "Shannon Mackeigan", 
                    "phone": "616-267-1162"
                }, 
                "facility": {
                    "address": {
                        "city": "Grand Rapids", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49503"
                    }, 
                    "name": "Helen DeVos Children's Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Albert Cornelius, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Giselle Sholler, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mccormk@musc.edu", 
                    "last_name": "Kate McCormack, RN", 
                    "phone": "843-792-3379"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Amy-Lee Bredlau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.", 
        "overall_contact": {
            "email": "genevieve.bergendahl@helendevoschildrens.org", 
            "last_name": "Genevieve Bergendahl, RN", 
            "phone": "616-267-0335"
        }, 
        "overall_contact_backup": {
            "email": "alyssa.vanderwerff@helendevoschildrens.org", 
            "last_name": "Alyssa VanderWerff", 
            "phone": "(616) 267-0327"
        }, 
        "overall_official": [
            {
                "affiliation": "The Spectrum Health Group", 
                "last_name": "Giselle Sholler, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Helen DeVos Children's Hospital", 
                "last_name": "Albert Cornelius, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the activity of Vismodegib based on Progression Free Survival (PFS) in pediatric and adolescent subjects with refractory or recurrent pontine glioma.", 
            "measure": "Determine the Progression Free Survival (PFS) of Participants using days until progression", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774253"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Spectrum Health Hospitals", 
            "investigator_full_name": "Giselle Sholler", 
            "investigator_title": "Study Chair", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the safety and tolerability of Vismodegib as a single agent in pediatric and young adult patients with refractory or recurrent pontine glioma", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Overall Survival (OS) and clinical benefit (ORR + stable disease, SD)", 
                "measure": "Determine the Median overall survival (OS) of Participants", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To evaluate the impact of QOL of children receiving Vismodegib", 
                "measure": "Evaluate the impact of Quality of Life of children receiving Vismodegib using PedsQL questionnaires", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To determine the objective response rates (partial and complete response) for patients without and with evidence of activation of Hedgehog signaling pathway in their tumors", 
                "measure": "Determine the response rates of Participants based on activation (or no activation) of their hedgehog signaling pathway", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Spectrum Health Hospitals", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Spectrum Health Hospitals", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Phoenix Children's Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Giselle Sholler", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}